Clinical Trials
5 trialsNCT07518173 2026-06-04
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06968585 2026-05-08
A166
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05705401 2026-04-27
HERO
NRG Oncology
Phase 3 Active not recruiting
NCT03975647 2026-03-30
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT07043725 2026-03-27
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting